MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/130/0.1/16.01.26 | Real-time Bid/Ask 09:26:44 01/07/2024 pm IST | ||
| 3.42 EUR / 3.43 EUR | +3.47% |
|
| Current month | +25.86% | ||
| 1 month | +24.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 01/24/01 | 3.26 | -1.51% |
| 28/24/28 | 3.31 | -1.19% |
| 27/24/27 | 3.35 | 0.00% |
| 26/24/26 | 3.35 | -4.01% |
| 25/24/25 | 3.49 | +10.09% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 06:20 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME1GBH |
| ISIN | DE000ME1GBH7 |
| Date issued | 03/10/2023 |
| Strike | 130 $ |
| Maturity | 16/01/2026 (564 Days) |
| Parity | 10 : 1 |
| Emission price | 0.93 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.49 € |
|---|---|
| Lowest since issue | 0.87 € |
| Spread | 0.01 € |
| Spread % | 0.29% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Warrants
- Warrant
